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Abstract
Introduction: Susceptibility to amyotrophic lateral sclerosis (ALS) is associated with smoking in some studies, but it is not
clear which aspect of smoking behavior is related. Using detailed records of lifetime smoking we investigated the relation-
ship between smoking and ALS in a UK population. Methods: In this retrospective case-control study, smoking status
was collected using environmental questionnaires from people diagnosed with ALS between 2008 and 2013 and from
age, sex and geographically matched controls. Categorical measures of smoking behavior were: smoking at the time of
survey and smoking initiation; continuous measures were intensity (cigarettes per day), duration (years from starting to
stopping or time of survey), cigarette pack years, and comprehensive smoking index (CSI), a measure of lifetime smok-
ing. We used logistic regression to assess the risk of ALS with different combinations of smoking variables adjusted for
age at survey, gender, level of education, smoking status and alcohol initiation, selecting the best model using the Akaike
Information Criterion. Results: There were 388 records with full smoking history. The best-fitting model used CSI and
smoking status at the time of survey. We found a weak association between current smoking and risk of ALS, OR 3.63
(95% CI 1.02–13.9) p value 0.05. Increase in CSI score did not increase risk of ALS: OR 0.81 (95% CI 0.58–1.11) p
value 0.2.Conclusion: There is weak evidence of a positive effect of current smoking on the risk of ALS which does not
show dose-dependence with higher levels of lifetime smoking and maybe a false positive result.
Keywords: Amyotrophic lateral sclerosis, smoking, case control
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disease characterized by progressive
death of motor neurons leading to relentlessly wor-
sening weakness and death, usually from respira-
tory failure due to involvement of the diaphragm,
2–3 years after diagnosis (1,2) Although there is
an evident genetic component, heritability studies
indicate that environmental (and probably stochas-
tic) factors also contribute (3–6).
There is evidence from multiple studies that
smoking is associated with ALS, but no agreement
over which aspect of smoking behavior is related to
ALS (7–14). Despite an evidence-based literature
review that concluded that smoking can be consid-
ered a risk factor for ALS, it remains unclear if
there is a dose-response effect, or what the bio-
logical mechanism might be (15). In addition, con-
founding cannot be discounted, since ALS is also
associated with military service, education and
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socioeconomic status, which are also associated
with smoking status (16,17). It is biologically plaus-
ible that smoking could be a risk factor through oxi-
dative stress or exposure to potentially neurotoxic
chemicals, and so it remains an attractive candidate
for studies of environmental etiology (18,19).
The comprehensive smoking index (CSI) esti-
mates lifetime smoking by combining duration,
intensity and time since cessation into a score
allowing all factors to be considered while avoiding
issues of multicollinearity between smoking expos-
ure variables (20). CSI has not previously been
used to investigate the role of smoking in
ALS risk.
We, therefore, analyzed retrospective case-con-
trol data to determine whether smoking is related
to ALS in a UK population, investigating the rela-
tionship between different smoking variables
including CSI and other regularly used measures,
and risk of ALS.
Methods
Case-control study design
The data were obtained from the Motor Neurone
Disease Association of England, Wales and
Northern Ireland (MNDA) Collections collected
as part of the MNDA Epidemiology Study, REC
reference 07/MRE01/57. People diagnosed with
definite, probable or possible ALS according to the
El Escorial criteria between 2008 and 2013 were
included (21). Three tertiary centers in London,
Sheffield, and Birmingham acted as data collection
hubs but people with ALS were recruited at sec-
ondary centers such as district general hospitals,
therefore these are incident cases representative of
the ALS population. General practitioners from
the general practice of the person with ALS were
asked to invite 10 healthy controls to participate in
the study via post. The research team matched
people on age (within 5 years of the person with
ALS) and gender in a 1:1 ratio. Four hundred and
thirteen participants provided informed consent,
405 undertook a telephone interview about their
lifestyle including smoking undertaken by a trained
nurse. Three participants gave no information on
smoking behavior.
Definition of smoking status
Categorical measures were: smoking at the time of
survey (current, former, never), smoking initiation
(ever, never).
To define former smokers we used logistic
regression modeling to compare ALS risk between
current smokers and ex-smokers, using never
smokers as a reference. Few people had recently
quit (n¼3 within one year of survey) so we
grouped ex-smokers into 5-year time since
cessation intervals up to 20 years which was aggre-
gated to 20þ. ALS risk reduced from an odds ratio
of 2.02–0.79 for current smokers compared to
people who had quit within 5 years so former
smokers were defined as having given up at least a
day before the survey.
Continuous measures included: intensity (ciga-
rettes per day), duration of smoking (years from start-
ing to stopping or time of survey), pack years
(intensityduration), and CSI. The CSI is a non-
linear model of smoking exposure that combines dur-
ation of smoking, time since cessation and smoking
intensity into a continuous score which can be used
in a regression model representing lifetime smoking
(20). The model involves the simulation of tau and
delta from the dataset. Delta, or half-life, reflects the
exponential decay in the effect of smoking on health
outcomes during a lifetime. Tau, or lag-time, reflects
that smokers may be at a higher risk of disease imme-
diately after quitting due to reverse causality. The
equations for CSI are as follows:
tsc ¼ maxðtscd, 0Þ
dur ¼ maxðdurþ tscd, 0Þ–tsc
comprehensive smoking index
¼ ð1–0:5dur=sÞ ð0:5tsc=sÞ lnðintþ 1Þ
tsc: time since cessation; d: lag time; tss: time
started smoking; dur: duration of smoking (calcu-
lated as age-tss for people currently smoking or
[age-tsc]-tss for former smokers); s: half-life; int:
cigarettes per day.
Logistic regression
Data were analyzed using R (22). Continuous
demographic characteristics were compared by
Student’s t-test or Mann-Whitney U test.
Categorical variables were compared by chi-
squared or Fisher’s exact test. The primary out-
come, whether smoking increases the risk of ALS,
was analyzed using logistic regression with max-
imum likelihood estimation. We generated eight
models with combinations of one categorical and
one continuous measure of smoking, comparing
the Akaike Information Criterion (AIC) of the
models to assess fit (23). Odds ratios were
adjusted for age, educational attainment, gender,
and alcohol consumption.
Assuming an odds ratio of 1.8, a 20% smoking
rate in the control population and alpha of 0.05,
we had 71% power with a sample size of 400 cases
and controls in a 1:1 ratio.
Results
There were 202 cases and 200 control records
available for analysis. The two groups were similar
except for educational attainment and alcohol sta-
tus. The details are shown in Table 1.
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The optimal CSI variables were tau ¼ 2 and
delta ¼ 3.6. There were no differences between
groups in unadjusted smoking behaviors, as shown
in Table 2.
Three hundred eighty-eight records had full
smoking history available for logistic regression
analysis. Table 3 gives the results of the best fit-
ting logistic regression model which included the
CSI and smoking status at time of survey with
AIC 543.77. The highest AIC, representing the
worst fitting model, was for smoking initiation
and number of cigarettes per day at 553.23. An
increase in the value of CSI did not increase the
risk of ALS: OR 0.81 (95% CI 0.57–1.11) p
value 0.2. Current smoking increased the risk of
ALS, OR 3.62 (95% CI 1.02–13.9) p value ¼
0.05, a Bonferroni correction shows that this is
likely a false positive result because of mul-
tiple testing.
Discussion
We found a weak association between current
smoking and risk of ALS using traditional epidemi-
ology methods to explore association. We report an
uncorrected p-value of 0.05, and several models
tested for fit, suggesting that this is, in fact, a false-
positive result. We also found that using CSI to
measure lifetime smoking exposure resulted in a
better fitting model for our data than using cigarette
pack years but we found no evidence of a dose-
dependent response of ALS risk to smoking.
Our results are similar to those from a study
conducted in the Netherlands which found current
smoking to be associated with ALS in an incident
cohort but no strong dose-dependent relationship
(9). The strength of the association between smok-
ing and ALS was reported as weak in a meta-ana-
lysis of case-control and cohort studies, with a
higher effect in women (7). This weakness may be
Table 1. Unadjusted comparisons of demographics and behavior in ALS cases and controls.
Demographic/behavioral measure Case (n5 202) Control (n5 200) p Value (test)
Gender ratio, Female: Male % (n) 41:59 (85:117) 44:56 (88:112) 0.77 (Chi-squared test)
Educational attainment % (n)
Primary school 1.5 (3) 1 (2) 0.0041 (Fisher’s exact test)
Secondary school 38.1 (77) 30.5 (61)
College 31.2 (63) 23.5 (47)
Technical school 8.4 (17) 12 (24)
University 14.4 (29) 29 (58)
Other 5.5 (12) 3.5 (7)
Missing 0.5 (1) 0.5 (1) Not analyzed
Mean age at survey (standard deviation) 63.1 (10.53) 64.5 (10.52) 0.12 (t-test)
Alcohol use % (n)
Alcohol status 8:62 (17:184) 12:88 0.32
Never: Ever (24:176) (Fisher’s exact test)
Site of onset % (n)
Bulbar 21.7 (44) n/a
Spinal 73.3 (148) n/a
Not known/recorded 5 (10) n/a
Mean age at onset (SD) 60.7 (10.6) n/a
Median months onset–diagnosis (IQR) 12 (13) n/a
Median months onset– survey (IQR) 28.1 (21.5) n/a
The three centers are tertiary referral centers with about a third of the patients diagnosed at the center, and the remainder diagnosed
elsewhere first. SD: standard deviation; IQR: interquartile range; n/a: not applicable.
Table 2. Smoking variables and crude comparisons.
Smoking measure Case Control p Value
Smoking behavior % (n)
Smoking initiation
(ever smokers)
47
(94)
53
(105)
0.27
Smoking status 47:44:9 53:44:3 0.065
Never : Former : Current (94:90:18) (105:88:7)
Median age smoking initiation (n) 16±3 (108) 16±3.5(94) 0.94
Median cigarettes per day (n) 17±10 15±10 0.88
Median duration smoking 23.5± 25.6 23±24 0.58
Median cigarette pack years 20±27.27 16±28.4 0.7
Median comprehensive smoking index values 0.031±1.85 0.0053±1.36 0.33
Chi squared tests were used for categorical variables and Mann-Whitney U for continuous variables as all were non-normally
distributed. Six people were missing duration information, 4 missing smoking intensity. Records with missing data were excluded
from analysis.
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due to the reliance on prevalent and clinic cohorts
which would under-represent smokers because
their survival is shorter (9).
A pooled analysis of prospective studies found
that there was an increased risk of ALS in former
and current smokers (13). Two large prospective
cohort studies included in the pooled analysis were
originally set up as prospective studies into envir-
onmental exposures and cancer risk (11,14).
People with ALS were identified from death certif-
icates, which may over-represent people who
smoke as their survival is shorter.
The CSI is more useful than cigarette pack
years to investigate dose-dependency, as it formally
considers the decreased risk of disease after smok-
ing cessation. The CSI had a bimodal distribution
of smoking exposure in both cases and controls,
corresponding to smoking at the time of survey
(Figure 1). The mean CSI of current smokers is
slightly higher in cases than controls and so dose-
dependency in current smokers should be investi-
gated further.
Median age of smoking initiation was around
the late teens in both groups, and it has been
reported that frontotemporal dementia, a behav-
ioral change that occurs in some people with ALS
is not associated with smoking behaviors, so the
association is unlikely to reflect reverse causal-
ity (24).
The strengths of this study are that we have
detailed environmental data on incident cases of
ALS and controls. A limitation is the sample size
which means it is only powered to detect relatively
large effect sizes with odds ratios of the order of
1.8 or higher. Retrospective case-control studies
generally suffer from recall bias. This study may
suffer the effect of two opposing sample biases:
people in an environmental study of lifestyle may
be more likely to smoke heavily, and some people
in this ALS study attended specialist clinics so
Table 3. Best fitting logistic regression model for smoking and risk of ALS.
Variable Odds ratio Lower CI Upper CI p Value
Smoking status
Current smoker 3.62 1.02 13.8 0.05
Former smoker 1.08 0.67 1.74 0.74
Comprehensive smoking index 0.81 0.58 1.11 0.2
Age 0.98 0.96 1 0.07
Ever drinker 1.33 0.65 2.75 0.43
Male 1.05 0.68 1.63 0.83
Education level
Primary school 2 0.05 78.4 0.68
Secondary school 1.27 0.05 33.2 0.87
Technical school 0.73 0.03 19.4 0.83
College 1.32 0.05 34.4 0.85
University 0.44 0.02 11.7 0.58
Other 1.6 0.06 45.7 0.75
Figure 1. (a) Density plot of CSI value by case control status. (b) Box plot of CSI value by smoking status at time of survey, points
colored by case control status. Both graphs are in ever smokers only.
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may be less likely to smoke. Additionally, we do
not know how many controls who were contacted
declined to participate, so the control population
may be biased. There were no current smokers in
the controls recruited in London, although a sub-
group analysis in the other two areas shows that
odds ratios for current smoking are consistent
between the remaining areas.
We found that people with ALS were less likely
to drink alcohol, but our survey responses do not
support a protective relationship as ALS was cited
as the reason for not drinking in most cases.
Despite controlling for drinking and educational
status, it is not possible to completely rule out the
effects of confounding.
In this study of smoking and ALS, we do not
find strong evidence to support smoking as a risk
factor, even using lifetime smoking exposure as
measured by the CSI.
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